XML 82 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Operating Activities      
Net loss $ (98,188)us-gaap_NetIncomeLoss $ (51,145)us-gaap_NetIncomeLoss $ (14,562)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities      
Depreciation 127us-gaap_Depreciation 20us-gaap_Depreciation 31us-gaap_Depreciation
Amortization of debt issuance costs   88us-gaap_AmortizationOfFinancingCosts 47us-gaap_AmortizationOfFinancingCosts
Accretion of debt discount   87us-gaap_AccretionExpense 59us-gaap_AccretionExpense
Amortization of premium and discounts on investment securities 2,024us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium    
Non-cash change in fair value of warrant liability   1,181us-gaap_FairValueAdjustmentOfWarrants 366us-gaap_FairValueAdjustmentOfWarrants
Loss on extinguishment of debt   1,091us-gaap_GainsLossesOnExtinguishmentOfDebt  
Deferred income taxes (18,798)us-gaap_DeferredIncomeTaxesAndTaxCredits    
Share-based compensation 13,040us-gaap_ShareBasedCompensation 2,871us-gaap_ShareBasedCompensation 640us-gaap_ShareBasedCompensation
Excess tax benefits from share-based compensation (4,256)us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities    
Changes in operating assets and liabilities:      
Due from Novartis Pharma, AG (960)us-gaap_IncreaseDecreaseInContractReceivablesNet    
Prepaid expense and other current assets (2,008)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (6,761)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets 21us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Accrued interest receivable 280us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet    
Security deposits (27)us-gaap_IncreaseDecreaseInSecurityDeposits (96)us-gaap_IncreaseDecreaseInSecurityDeposits  
Other assets (100)us-gaap_IncreaseDecreaseInOtherNoncurrentAssets   1,036us-gaap_IncreaseDecreaseInOtherNoncurrentAssets
Accrued research and development expenses 5,433opht_IncreaseDecreaseInAccruedResearchAndDevelopment 1,472opht_IncreaseDecreaseInAccruedResearchAndDevelopment (485)opht_IncreaseDecreaseInAccruedResearchAndDevelopment
Accounts payable and accrued expenses 4,897us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 2,417us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (257)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Deferred revenue 209,624us-gaap_IncreaseDecreaseInDeferredRevenue    
Net cash provided by (used in) operating activities 111,088us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (48,775)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (13,104)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Investing Activities      
Purchase of marketable securities (597,762)us-gaap_PaymentsToAcquireMarketableSecurities    
Maturities of marketable securities 171,600us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities    
Purchase of property and equipment (1,655)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (5)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment  
Net cash used in investing activities (427,817)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (5)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations  
Financing Activities      
Payment of debt issuance costs   (43)us-gaap_PaymentsOfDebtIssuanceCosts (377)us-gaap_PaymentsOfDebtIssuanceCosts
Proceeds from stock option/warrant exercises 2,949opht_ProceedsFromStockOptionsAndWarrantsExercised 94opht_ProceedsFromStockOptionsAndWarrantsExercised 2opht_ProceedsFromStockOptionsAndWarrantsExercised
Proceeds from follow-on public offering, net 55,409opht_ProceedsFromFollowOnPublicOfferingNet    
Proceeds from initial public offering, net   175,555opht_ProceedsFromIssuanceInitialPublicOfferingNet  
Excess tax benefits from share-based compensation 4,256us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities    
Repayment of venture debt facility, net   (11,900)opht_ProceedsFromRepaymentsOfVentureDebtFacility 11,387opht_ProceedsFromRepaymentsOfVentureDebtFacility
Proceeds from issuance of preferred stock, net   49,699us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock  
Proceeds from royalty purchase agreement 83,333us-gaap_ProceedsFromOtherDebt 41,667us-gaap_ProceedsFromOtherDebt  
Net cash provided by financing activities 145,947us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 255,072us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 11,012us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Net change in cash and cash equivalents (170,782)us-gaap_NetCashProvidedByUsedInContinuingOperations 206,292us-gaap_NetCashProvidedByUsedInContinuingOperations (2,092)us-gaap_NetCashProvidedByUsedInContinuingOperations
Cash and cash equivalents      
Beginning of period 210,596us-gaap_CashAndCashEquivalentsAtCarryingValue 4,304us-gaap_CashAndCashEquivalentsAtCarryingValue 6,396us-gaap_CashAndCashEquivalentsAtCarryingValue
End of period 39,814us-gaap_CashAndCashEquivalentsAtCarryingValue 210,596us-gaap_CashAndCashEquivalentsAtCarryingValue 4,304us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosure of cash paid      
Interest   1,523us-gaap_InterestPaid 437us-gaap_InterestPaid
Income Taxes 40,159us-gaap_IncomeTaxesPaid    
Supplemental disclosures of non-cash information related to investing activities      
Change in unrealized loss in marketable securities, net of tax (65)us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments    
Supplemental disclosures of cash flow information      
Conversion of preferred stock to common stock upon completion of IPO   174,310us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities  
Accreted dividends on Series A, Series A-1, Series of B, B-1 and Series C Preferred Stock   $ 5,891us-gaap_TemporaryEquityDividendsAdjustment $ 7,063us-gaap_TemporaryEquityDividendsAdjustment